Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28023037 | 0.83 | HTR6 (0.46) | HTR6PSIP1KDM4ECA1CA2 | |
| SCHEMBL778854 | 0.82 | HTR6 (0.50) | HTR6PSIP1KDM4ECA1CA2 | |
| SCHEMBL4327138 | 0.82 | HTR6 (0.50) | HTR6PSIP1KDM4ECA1CA2 | |
| SCHEMBL5016541 | 0.78 | CA12 (0.48) | HTR6PSIP1KDM4ECA1CA2 | |
| SCHEMBL10934741 | 0.78 | HTR6 (0.46) | HTR6PSIP1KDM4ECA1CA2 | |
| SCHEMBL25001334 | 0.78 | HTR6 (0.46) | HTR6PSIP1KDM4ECA1CA2 | |
| SCHEMBL9385444 | 0.78 | GAA (0.54) | KDM4ECA1CA2TSHRSMN1; SMN2 | |
| SCHEMBL16623120 | 0.78 | HTR6 (0.46) | HTR6PSIP1KDM4ECA1CA2 | |
| SCHEMBL3328706 | 0.78 | TSHR (0.48) | HTR6PSIP1KDM4ECA1CA2 | |
| SCHEMBL776304 | 0.78 | HTR6 (0.46) | HTR6PSIP1KDM4ECA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142946-A1 | Modified nucleosides and nucleotides and use thereof | CHATTOPADHYAYA JYOTI (SE) | 2004-07-22 | — | — | US | claimed |
| EP-1332150-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES AND USE THEREOF | Chattopadhyaya, Jyoti (SE) | 2003-08-06 | — | — | EP | claimed |
| WO-2002038578-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES AND USE THEREOF | CHATTOPADHYAYA JYOTI (SE) | 2002-05-16 | — | — | WO | claimed |
| US-5721350-A | Deuterated nucleosides | CHATTOPADHYAYA JYOTI (SE) | 1998-02-24 | — | — | US | claimed |
| EP-2177519-B1 | TETRAZOYLOXIME DERIVATIVE AND PLANT DISEASE CONTROL AGENT | NIPPON SODA CO (JP) | 2015-05-27 | — | — | EP | disclosed |
| US-9029552-B2 | Tetrazoyloxime derivative and plant disease control agent | NIPPON SODA CO., LTD. (JP) | 2015-05-12 | — | — | US | disclosed |
| US-20140005385-A1 | TETRAZOYLOXIME DERIVATIVE AND PLANT DISEASE CONTROL AGENT | NIPPON SODA CO., LTD. (JP) | 2014-01-02 | — | — | US | disclosed |
| EP-2669282-A1 | Tetrazoyloxime derivative and plant disease control agent | NIPPON SODA CO., LTD. (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-20100137594-A1 | TETRAZOYLOXIME DERIVATIVE AND PLANT DISEASE CONTROL AGENT | NIPPON SODA CO., LTD. (JP) | 2010-06-03 | — | — | US | disclosed |
| EP-2177519-A1 | TETRAZOYLOXIME DERIVATIVE AND PLANT DISEASE CONTROL AGENT | Nippon Soda Co., Ltd. (JP) | 2010-04-21 | — | — | EP | disclosed |
| WO-1999014189-A1 | AMINO ACID DERIVATIVES | HYUNDAI PHARM. IND. CO., LTD. (KR) | 1999-03-25 | — | — | WO | disclosed |
| WO-1999014189-A1 | AMINO ACID DERIVATIVES | HYUNDAI PHARM. IND. CO., LTD. (KR) | 1999-03-25 | — | — | WO | disclosed |
| EP-0594624-A4 | DYNEMICIN ANALOGS: SYNTHESES, METHODS OF PREPARATION AND USE. | SCRIPPS CLINIC RES (US) | 1994-02-21 | — | — | EP | disclosed |
| US-5281710-A | Antibiotics or antitumor agents | THE SCRIPPS RESEARCH INSTITUTE (US) | 1994-01-25 | — | — | US | disclosed |
| WO-1994001113-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-01-20 | — | — | WO | disclosed |
| US-5276159-A | Antitumor | THE SCRIPPS RESEARCH INSTITUTE (US) | 1994-01-04 | — | — | US | disclosed |
| US-5225402-A | Vasopressin antagonist, vasodilation, hypotensive, diuretics and anticoagulants | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-06 | — | — | US | disclosed |
| WO-1992002522-A1 | DYNEMICIN ANALOGS: SYNTHESES, METHODS OF PREPARATION AND USE | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1992-02-20 | — | — | WO | disclosed |
| EP-0382185-A2 | Carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-16 | — | — | EP | disclosed |
| US-4495270-A | RAPIDLY FORMS IMAGES HAVING HIGH IMAGE DENSITY | FUJI PHOTO FILM CO., LTD. (JP) | 1985-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142946-A1 | Modified nucleosides and nucleotides and use thereof | RNASEH1, RNASEL, NSUN2 | HTR6 861/4885PSIP1 3898/4885KDM4E 1990/4885 |
| US-20140005385-A1 | TETRAZOYLOXIME DERIVATIVE AND PLANT DISEASE CONTROL AGENT | PAOX, BROX, TTI2 | HTR6 4728/4885PSIP1 2518/4885KDM4E 1840/4885 |
| US-20100137594-A1 | TETRAZOYLOXIME DERIVATIVE AND PLANT DISEASE CONTROL AGENT | PAOX, H1-10, HAX1 | HTR6 3671/4885PSIP1 4363/4885KDM4E 2640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.